Evaluation of lincomycin in drinking water for treatment of induced porcine proliferative enteropathy using a Swine challenge model.
A single-location, challenge-model study was conducted to evaluate the effectiveness of lincomycin against porcine proliferative enteropathy when administered through the drinking water at 125 and 250 mg/gallon. The primary variables of interest were pig removal rate, diarrhea scores, demeanor scores, and abdominal appearance scores. Ancillary performance variables examined included average daily feed intake, average daily gain, and feed per gain. After a 3-day acclimation period, pigs were challenged on 2 consecutive days with a mucosal homogenate containing a total dose of 1.4 x 10(9) cells of Lawsonia intracellularis. Five days later, when porcine proliferative enteropathy was well established, drinking water medicated with 125 mg (L125) or 250 mg (L250) lincomycin/gallon was provided to two groups of pigs for 10 days. Pigs were observed for 13 days following the treatment period. A third group of pigs served as controls and received unmedicated drinking water throughout the study. The L250 group experienced a significantly lower (P < .05) pig removal rate than the control group over the 23-day observation period. Additionally, for every primary variable, the L250 group experienced a significantly decreased (P < .01) number of abnormal days compared with the control group. The L125 group showed a significant reduction (P < .05) in abnormal demeanor and abnormal abdominal appearance scores compared with controls.
Bradford
James R
JR
Pfizer Animal Health, 7000 Portage Rd, Kalamazoo, MI, 49001, USA.
Winkelman
Nathan L
NL
Moreira
Frederico P
FP
Elfring
Gregory D
GD
D000284:Administration, Oral; D000818:Animals; D000900:Anti-Bacterial Agents / Q000008:administration & dosage / Q000627:therapeutic use*; D045824:Desulfovibrionaceae Infections / Q000188:drug therapy / Q000662:veterinary*; D004305:Dose-Response Relationship, Drug; D004326:Drinking; D005260:Female; D020639:Lawsonia Bacteria / Q000187:drug effects*; D008034:Lincomycin / Q000008:administration & dosage / Q000627:therapeutic use*; D008297:Male; D011897:Random Allocation; D013552:Swine; D013553:Swine Diseases / Q000188:drug therapy*; D016896:Treatment Outcome
D000900:Anti-Bacterial Agents; D008034:Lincomycin